Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil

Anti-Cancer Drugs

Volumn 8, Issue 3, 1997, Pages 293-295

  Strumberg, Dirk ^a   Harstrick, Andreas ^a   Klaassen, Ute ^a   Müller, Christian ^a   Eberhardt, Wilfried ^a   Korn, Michael W ^a   Wilke, Hansjochen ^a   Seeber, Siegfried ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

5 FU resistance; colorectal cancer; phase II; trofosfamide

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; FLUOROURACIL; FOLINIC ACID; METOCLOPRAMIDE; TROFOSFAMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG RESPONSE; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; COLORECTAL NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 0030888587     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199703000-00012     Document Type: Article

References (14)

1. Cohen AM, Minsky BD, Schilsky RL. Colon cancer. In: DeVita VT, Hellman S, Rosenberg, eds. Cancer: principles and practice of oncology. Philadelphia: Lippincott 1993; 929-67.
2. Köhne-Wömpner CH, Schmoll HJ, Harstrick A, Rustum YM. Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. Semin Oncol 1992; 19: 105-25.
3. Carter SK, Friedman M. Integration of chemotherapy into combined modality treatment of solid tumors. II. Large bowel carcinoma. Cancer Treat Rev 1974; 1: 111-20.
4. Boos J, Küpker F, Blaschke G, Jürgens H. Trofosfamide metabolism in different species - ifosfamide is the predominant metabolite. Cancer Chemother Pharmacol 1993; 33: 71-6.
5. Struck RF, Schmid SM, Waud WR. Antitumor activity of halogen analogs of phosphoramide, isophosphoramide, and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide. ifosfamide, and trofosfamide. Cancer Chemother Pharmacol 1994; 34: 191-6.
6. Brock N. Pharmacologische Untersuchungen mit Trofosfamid (Ixoten), einem neuen Oxazaphosphorinoxid. Med Monatsschr 1973; 27: 300.
7. Wist E, Risherg T. Trofosfamide in non-Hodgkin's lymphoma. A phase II study. Acta Oncol 1979; 30: 819-21.
8. Falkson G, Falkson HC. Trofosfamide in the treatment of patients with cancer. A pilot trial. S Afr Med J 1978; 53: 886-8.
9. Pötzi P, Kühböck J, Aiginger P. Trofosfamide in malignant lymphomas and solid tumors. In: Proc 11th Int Congr of Chemotherapy and the 19th Interscience Conf on Antimicrobial Agents and Chemotherapy, Boston 1979: 2; 1516-8.
10. Scheef W, Exss R, Schnitker J, Soemer G. Trofosfamid in hoher Dosierung beim Mammakarzinom. Kranken-bausarzt 1984; 57: 935-42.
11. Kühböck J, Aiginger P, Pötzi O. Ixoten maintenance therapy in solid tumors and malignant lymphomas. In: Proc 13th Int Congr of Chemotherapy, Vienna 1983: 21-6.
12. Drings P, Allner R, Brock N, et al. Erfahrungen mit neuartigen N-Lost-Phosphoramidestern. Dtsch Med Wochenschr 1970; 95: 491-7.
13. Blomqvist C, Wiklund T, Pajunen M, Virolainen M, Elomaa I. Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma. Cancer Chemother Pharmacol 1995; 36: 263-5.
14. Brock N. Oxazaphosphorine cytostatics: past present-future. Seventh Cain Memorial Award Lecture. Cancer Res 1989; 49: 1-7.